SUPN · Nasdaq
It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.
Hover or tap a dot to see the filings behind that score.
Supernus Pharmaceuticals, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”). The Company is unable to file its Form 10-K within the prescribed time period without unreasonable effort or expense because it requires additional time to complete its financial statements and assessment of the Company’s internal control over financial reporting. As a result of the foregoing, KPMG LLP, the Company’s independent registered public accounting firm, has not yet completed its audit procedures. Based upon currently available information, the Company expects to report one or more material weaknesses in its internal controls and expects its internal control over financial reporting will be ineffective as of December 31, 2022. The material weaknesses have not resulted in any material misstatements or omissions in previously reported financial statements. The Company does not anticipate any material changes to the financial information furnished with the Form 8-K filed by the Company with the Securities and Exchange Commission on February 28, 2023. The Company anticipates that the Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date
NT 10-K, filed 2023-03-02 · material weakness
Supernus Pharmaceuticals, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-K for the year ended December 31, 2022 (the “Form 10-K”). The Company is unable to file its Form 10-K within the prescribed time period without unreasonable effort or expense because it requires additional time to complete its financial statements and assessment of the Company’s internal control over financial reporting. As a result of the foregoing, KPMG LLP, the Company’s independent registered public accounting firm, has not yet completed its audit procedures. Based upon currently available information, the Company expects to report one or more material weaknesses in its internal controls and expects its internal control over financial reporting will be ineffective as of December 31, 2022. The material weaknesses have not resulted in any material misstatements or omissions in previously reported financial statements. The Company does not anticipate any material changes to the financial information furnished with the Form 8-K filed by the Company with the Securities and Exchange Commission on February 28, 2023. The Company anticipates that the Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date
Supernus Pharmaceuticals, Inc. (the “Company”) is unable to file its quarterly report on Form 10-Q for the quarter ended March 31, 2022, without unreasonable effort or expense, due to a delay in obtaining and compiling information required to be included in its Form 10-Q. Such delay was a result of the Company’s late filing of its Annual Report on Form 10-K for the year ended December 31, 2021, which delay could not be eliminated by the Company without unreasonable effort and expense. The Company currently anticipates that its Form 10-Q for the quarter ended March 31, 2022 will be filed as soon as practicable, and no later than five days calendar days following its prescribed due date
Supernus Pharmaceuticals, Inc. (the “Company”) requires additional time to complete its financial statements and assessment of the Company’s internal controls over financial reporting for the following reasons. The Company announced on November 24, 2021 that it was the target of a ransomware attack. While the attack had no significant impact on the business and did not cause any long-term disruption to the Company’s operations, it caused the Company to (i) restore securely backed-up data into its legacy enterprise resource planning system (“ERP”), (ii) manually process certain functions previously automated in its legacy ERP, and (iii) simultaneously accelerate its planned transition from such legacy ERP to a more modern ERP. Also, on November 24, 2021, the Company completed its acquisition of Adamas Pharmaceuticals, Inc. (“Adamas”). As a result of the foregoing events commencing during the fourth quarter of 2021 and continuing into 2022, the Company is unable to file timely, without unreasonable effort and expense, its Annual Report on Form 10-K for the year ended December 31, 2021 (the “Form 10-K”). As a result of the facts and circumstances described above, the Company requires additional time to complete its financial statements and assessment of internal controls over financial reporting. As a further result of the foregoing, KPMG LLP, the Company’s independent registered public accounting firm, has been unable to complete its audit procedures. Based upon currently available information, the Company expects to report one or more material weaknesses in its internal controls over financial reporting, and expects its internal controls over financial reporting will be ineffective as of December 31, 2021. The material weaknesses have not resulted in any material misstatements or omissions in previously reported financial statements
Supernus Pharmaceuticals, Inc. (the “Company”) is unable to file timely, without unreasonable effort and expense, its Annual Report on Form 10-K for the year ended December 31, 2020 (the “Form 10-K”). Due to the complexity of accounting for a business combination, the Company requires additional time to complete additional documentation to prepare its financial statements and assessment of the Company’s internal control over financial reporting. The Company does not anticipate any material changes to the financial results furnished with the Form 8-K filed by the Company with the Securities and Exchange Commission on February 25, 2021. It is anticipated that the Form 10-K will be filed on or before the fifteenth calendar day following the prescribed due date of the Form 10-K
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice